Effects of human hepatocyte growth factor on the proliferation of human hepatocytes and hepatocellular carcinoma cell lines.
BACKGROUND
Hepatocyte growth factor (HGF) has been suggested to initiate both hepatocyte and tumor cell proliferation after partial hepatectomy, thereby supporting local tumor recurrence. The aim of this study was to clarify the role of HGF in the regeneration of human hepatocyte and the growth of residual hepatocellular carcinoma cells after liver resection.


METHODS
36 patients who underwent partial hepatectomy for hepatocellular carcinoma (HCC) or living liver donation have been analyzed for HGF serum levels at day -1 through day 5 following surgery using an enzyme-linked immunosorbent assay. Isolated human hepatocytes and HCC cell lines (Hep 3B, Hep G2) were treated either with recombinant human (rh)-HGF, or sera from the 36 patients in the presence or absence of anti-HGF in order to measure their proliferative capacity using (3)H-thymidine incorporation.


RESULTS
Basal HGF levels were significantly higher in HCC than in healthy patients (1,573 +/- 131 vs. 778 +/- 64 pg/ml; p < 0.001), however, the postoperative rise of HGF in healthy patients was higher (9,608 +/- 3111 vs. 2,060 +/- 148 pg/ml) than in HCC patients. Incubation of human hepatocytes and Hep 3B cells with rh-HGF revealed a dose-dependent increase in DNA synthesis, while anti-HGF partially abolished this effect. Sera from normal and resected HCC patients stimulated DNA synthesis only in human hepatocytes, whereas it was inhibited in HCC cell lines.


CONCLUSIONS
HGF plays an important role in hepatocyte proliferation but contrary to in vitro results, HGF does not play a major role for the progression of hepatocarcinoma cells in vivo.
Efimova
Ekaterina A
EA
Department of General, Visceral, and Transplantation Surgery, Charité, Campus Virchow Klinikum, Universitätsmedizin Berlin, Berlin, Germany.
Glanemann
M
M
Liu
L
L
Schumacher
G
G
Settmacher
U
U
Jonas
S
S
Langrehr
J M
JM
Neuhaus
P
P
Nüssler
A K
AK
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000473:pathology* / Q000503:physiopathology / Q000601:surgery; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D005260:Female; D006133:Growth Substances / Q000097:blood; D006498:Hepatectomy; D017228:Hepatocyte Growth Factor / Q000097:blood / Q000276:immunology / Q000494:pharmacology*; D022781:Hepatocytes / Q000473:pathology*; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000473:pathology* / Q000503:physiopathology / Q000601:surgery; D008115:Liver Regeneration / Q000187:drug effects; D016031:Liver Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000473:pathology; D011184:Postoperative Period; D011994:Recombinant Proteins / Q000494:pharmacology
D000906:Antibodies; D006133:Growth Substances; D011994:Recombinant Proteins; D017228:Hepatocyte Growth Factor